Contrasting Merck & Co., Inc. (MRK) and Cadence Pharmaceuticals (CADX)
Merck & Co., Inc. (NYSE: MRK) and Cadence Pharmaceuticals (NASDAQ:CADX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.
This table compares Merck & Co., Inc. and Cadence Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Merck & Co., Inc.||11.60%||27.08%||11.41%|
This table compares Merck & Co., Inc. and Cadence Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Merck & Co., Inc.||$39.81 billion||3.84||$3.92 billion||$1.03||54.52|
Merck & Co., Inc. has higher revenue and earnings than Cadence Pharmaceuticals.
Institutional and Insider Ownership
73.8% of Merck & Co., Inc. shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Merck & Co., Inc. pays an annual dividend of $1.88 per share and has a dividend yield of 3.3%. Cadence Pharmaceuticals does not pay a dividend. Merck & Co., Inc. pays out 182.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has increased its dividend for 5 consecutive years.
This is a breakdown of current ratings and target prices for Merck & Co., Inc. and Cadence Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Merck & Co., Inc.||1||8||9||0||2.44|
Merck & Co., Inc. currently has a consensus price target of $66.00, indicating a potential upside of 17.53%.
Merck & Co., Inc. beats Cadence Pharmaceuticals on 9 of the 10 factors compared between the two stocks.
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.
About Cadence Pharmaceuticals
Cadence Pharmaceuticals, Inc. (Cadence) is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. In March 2014, Mallinckrodt Plc acquired Cadence Pharmaceuticals, Inc. In March 2014, Mallinckrodt Plc completed the acquisition of Cadence Pharmaceuticals.
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.